Loading
Alcohol Use Disorder / Adiposity / Fatty Liver · Interventional Study
ClinicalTrials.gov · August 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered but not-yet-recruiting interventional trial designed to evaluate whether semaglutide combined with behavioural counselling achieves higher alcohol abstinence than counselling alone in patients with obesity and fatty liver disease over 16 weeks. No results are posted in this registry record, and the study design details (randomisation, blinding, control arm specification) are not fully described.
Interventional, Randomized, Parallel, Open label, Treatment purpose. Adiposity, Fatty Liver, Alcohol Use Disorder; age from 18 Years; to 80 Years. Intervention: Semaglutide Arm. Compared with: Control Arm — Active Comparator. n = 64. 1 site: Switzerland.
This is a registered but not-yet-recruiting interventional trial designed to evaluate whether semaglutide combined with behavioural counselling achieves higher alcohol abstinence than counselling alone in patients with obesity and fatty liver disease over 16 weeks. No results are posted in this registry record, and the study design details (randomisation, blinding, control arm specification) are not fully described.
No interim analyses, safety data, or efficacy outcomes are reported.
Once results are available, this trial will provide direct evidence on whether GLP-1 receptor agonist therapy can reduce alcohol consumption in patients with concurrent obesity and liver disease—a clinically relevant question given the high prevalence of these comorbidities. Practitioners should await published results before interpreting any clinical significance.
This is a registered interventional study not yet recruiting with no posted results; it represents planned work to test whether semaglutide plus counselling improves alcohol abstinence versus counselling alone in patients with obesity and fatty liver disease.
As stated by the source record.
Quoted from the source exactly as published.
Once results are available, this trial will provide direct evidence on whether GLP-1 receptor agonist therapy can reduce alcohol consumption in patients with concurrent obesity and liver disease—a clinically relevant question given the high prevalence of these comorbidities. Practitioners should await published results before interpreting any clinical significance.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06546384). This is a study registration, not published results. Lead sponsor: Insel Gruppe AG, University Hospital Bern. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 64 participants (ESTIMATED). Conditions: Adiposity, Fatty Liver, Alcohol Use Disorder. Interventions: DRUG: Semaglutide; BEHAVIORAL: Weight reduction recommendations (nutritional and exercise). Primary outcome measures: Proportion of patients achieving total alcohol abstinence (measured by negative PEth test) , From inclusion date (baseline) until end of the study, total duration 16 weeks per patient. Brief summary: There is evidence that alcoholic beverage consumption significantly interacts with food energy intake. Furthermore, there is accumulating evidence showing independent, combined, and modifying effects of alcohol and metabolic factors on the onset and progression of chronic liver disease. Preclinical and clinical data have showed that GLP-1 RA can decrease alcohol consumption, particularly in obese patients. Moreover there is evidence that semaglutide can improve the liver sinusoidal milieu in pre-clinical models of cirrhosis. In this study, the investigators aim to assess if patients treated with semaglutide and receiving counselling will achieve a significantly higher alcohol abstinence compared to patients only receiving counselling.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.